Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2013

01.05.2013 | Epidemiology

Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study

verfasst von: Sarah Nechuta, Wei Lu, Ying Zheng, Hui Cai, Ping-Ping Bao, Kai Gu, Wei Zheng, Xiao Ou Shu

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

We investigated the association of major comorbidities with breast cancer outcomes using the Shanghai Breast Cancer Survival Study, a population-based, prospective cohort study of Chinese women diagnosed with breast cancer. Analyses included 4,664 women diagnosed with stage I–III incident breast cancer aged 20–75 years (median age = 51) during 2002–2006. Women were interviewed at 3–11 months post-diagnosis (median = 6.4) and followed up by in-person interviews and linkage with the vital statistics registry. Multivariable hazard ratios (HRs) and (95 % confidence intervals (CIs)) for the associations of comorbidities with breast cancer outcomes were estimated using Cox regression models. After a median follow-up of 5.3 years (range: 0.64–8.9), 647 women died (516 from breast cancer) and 632 recurrence/metastases were documented. The main comorbidities reported included: hypertension (22.4 %), chronic gastritis (14.3 %), diabetes mellitus (6.2 %), chronic bronchitis/asthma (5.8 %), coronary heart disease (5.0 %), and stroke (2.2 %). Diabetes was associated with increased risk of total mortality (adjusted HR: 1.40 (1.06–1.85)) and non-breast cancer mortality (adjusted HR: 2.64 (1.63–4.27)), but not breast cancer-specific mortality (adjusted HR: 0.98 (0.68–1.41)), adjusting for socio-demographics, clinical characteristics, selected lifestyle factors, and other comorbidities. Women with a history of stroke had a non-significant increased risk of total mortality (adjusted HR: 1.42 (0.91–2.22)) and a significant increased risk of non-breast cancer mortality (adjusted HR: 2.52 (1.33–4.78)), but not breast cancer-specific mortality (adjusted HR: 0.78 (0.38–1.62)). Overall, none of the comorbidities investigated were significantly associated with recurrence. In this large prospective cohort of breast cancer survivors, diabetes was significantly associated with increased risk of total and non-breast cancer mortality, and history of stroke was associated with increased risk of non-breast cancer mortality.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr. Accessed 07 June 2012 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide. Lyon, France: International Agency for Research on Cancer. Available from: http://​globocan.​iarc.​fr. Accessed 07 June 2012
2.
Zurück zum Zitat American Cancer Society (2012) Breast cancer facts & figures 2011–2012. American Cancer Society, Atlanta American Cancer Society (2012) Breast cancer facts & figures 2011–2012. American Cancer Society, Atlanta
3.
Zurück zum Zitat Anderson G, Horvath J (2004) The growing burden of chronic disease in America. Public Health Rep 119:263–270PubMedCrossRef Anderson G, Horvath J (2004) The growing burden of chronic disease in America. Public Health Rep 119:263–270PubMedCrossRef
4.
Zurück zum Zitat Harlan LC, Klabunde CN, Ambs AH, Gibson T, Bernstein L, McTiernan A, Meeske K, Baumgartner KB, Ballard-Barbash R (2009) Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv 3:89–98PubMedCrossRef Harlan LC, Klabunde CN, Ambs AH, Gibson T, Bernstein L, McTiernan A, Meeske K, Baumgartner KB, Ballard-Barbash R (2009) Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv 3:89–98PubMedCrossRef
5.
Zurück zum Zitat Patnaik JL, Byers T, DiGuiseppi C, Denberg TD, Dabelea D (2011) The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer I 103:1101–1111CrossRef Patnaik JL, Byers T, DiGuiseppi C, Denberg TD, Dabelea D (2011) The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer I 103:1101–1111CrossRef
6.
Zurück zum Zitat Sheppard AJ, Chiarelli AM, Marrett LD, Nishri ED, Trudeau ME (2011) Stage at diagnosis and comorbidity influence breast cancer survival in first nations women in Ontario, Canada. Cancer Epidem Biomar 20:2160–2167CrossRef Sheppard AJ, Chiarelli AM, Marrett LD, Nishri ED, Trudeau ME (2011) Stage at diagnosis and comorbidity influence breast cancer survival in first nations women in Ontario, Canada. Cancer Epidem Biomar 20:2160–2167CrossRef
7.
Zurück zum Zitat Land LH, Dalton SO, Jensen MB, Ewertz M (2012) Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. Breast Cancer Res Treat 131:1013–1020PubMedCrossRef Land LH, Dalton SO, Jensen MB, Ewertz M (2012) Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. Breast Cancer Res Treat 131:1013–1020PubMedCrossRef
8.
Zurück zum Zitat Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast-cancer. Ann Intern Med 120:104–110PubMedCrossRef Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast-cancer. Ann Intern Med 120:104–110PubMedCrossRef
9.
Zurück zum Zitat Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA, Coebergh JW (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785PubMedCrossRef Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA, Coebergh JW (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785PubMedCrossRef
10.
Zurück zum Zitat Patterson RE, Flatt SW, Saquib N, Rock CL, Caan BJ, Parker BA, Laughlin GA, Erickson K, Thomson CA, Bardwell WA et al (2010) Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat 122:859–865PubMedCrossRef Patterson RE, Flatt SW, Saquib N, Rock CL, Caan BJ, Parker BA, Laughlin GA, Erickson K, Thomson CA, Bardwell WA et al (2010) Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat 122:859–865PubMedCrossRef
11.
Zurück zum Zitat Land LH, Dalton SO, Jorgensen TL, Ewertz M (2012) Comorbidity and survival after early breast cancer. A review. Crit Rev Oncol Hematol 81:196–205PubMedCrossRef Land LH, Dalton SO, Jorgensen TL, Ewertz M (2012) Comorbidity and survival after early breast cancer. A review. Crit Rev Oncol Hematol 81:196–205PubMedCrossRef
12.
Zurück zum Zitat West DW, Satariano WA, Ragland DR, Hiatt RA (1996) Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 6:413–419PubMedCrossRef West DW, Satariano WA, Ragland DR, Hiatt RA (1996) Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 6:413–419PubMedCrossRef
13.
Zurück zum Zitat Nagel G, Wedding U, Rohrig B, Katenkamp D (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130:664–670PubMedCrossRef Nagel G, Wedding U, Rohrig B, Katenkamp D (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130:664–670PubMedCrossRef
14.
Zurück zum Zitat Houterman S, Janssen-Heijnen MLG, Verheij CDGW, Louwman WJ, Vreugdenhil G, van der Sangen MJC, Coebergh JWW (2004) Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Brit J Cancer 90:2332–2337PubMed Houterman S, Janssen-Heijnen MLG, Verheij CDGW, Louwman WJ, Vreugdenhil G, van der Sangen MJC, Coebergh JWW (2004) Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Brit J Cancer 90:2332–2337PubMed
15.
Zurück zum Zitat Maskarinec G, Pagano IS, Yamashiro G, Issell BF (2003) Influences of ethnicity, treatment, and comorbidity on breast cancer survival in Hawaii. J Clin Epidemiol 56:678–685PubMedCrossRef Maskarinec G, Pagano IS, Yamashiro G, Issell BF (2003) Influences of ethnicity, treatment, and comorbidity on breast cancer survival in Hawaii. J Clin Epidemiol 56:678–685PubMedCrossRef
16.
Zurück zum Zitat Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441–2447PubMedCrossRef Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441–2447PubMedCrossRef
17.
Zurück zum Zitat Cronin-Fenton DP, Norgaard M, Jacobsen J, Garne JP, Ewertz M, Lash TL, Sorensen HT (2007) Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer 96:1462–1468PubMed Cronin-Fenton DP, Norgaard M, Jacobsen J, Garne JP, Ewertz M, Lash TL, Sorensen HT (2007) Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer 96:1462–1468PubMed
18.
Zurück zum Zitat Dalton SO, Ross L, Duering M, Carlsen K, Mortensen PB, Lynch J, Johansen C (2007) Influence of socioeconomic factors on survival after breast cancer—a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983–1999. Int J Cancer 121:2524–2531PubMedCrossRef Dalton SO, Ross L, Duering M, Carlsen K, Mortensen PB, Lynch J, Johansen C (2007) Influence of socioeconomic factors on survival after breast cancer—a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983–1999. Int J Cancer 121:2524–2531PubMedCrossRef
19.
Zurück zum Zitat Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Warnberg F, Lambe M (2012) Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat 135:281–289PubMedCrossRef Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Warnberg F, Lambe M (2012) Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat 135:281–289PubMedCrossRef
20.
Zurück zum Zitat Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L (2009) Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer 124:1213–1219PubMedCrossRef Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L (2009) Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer 124:1213–1219PubMedCrossRef
21.
Zurück zum Zitat McCaskill-Stevens W, Abrams JS (2011) Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes? J Natl Cancer I 103:1072–1073CrossRef McCaskill-Stevens W, Abrams JS (2011) Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes? J Natl Cancer I 103:1072–1073CrossRef
22.
Zurück zum Zitat Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc 285:885–892CrossRef Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc 285:885–892CrossRef
23.
Zurück zum Zitat Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW (2007) Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 43:2179–2193PubMedCrossRef Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW (2007) Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 43:2179–2193PubMedCrossRef
24.
Zurück zum Zitat Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13(3):R64PubMedCrossRef Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13(3):R64PubMedCrossRef
25.
Zurück zum Zitat Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W (2009) Soy food intake and breast cancer survival. JAMA 302:2437–2443PubMedCrossRef Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W (2009) Soy food intake and breast cancer survival. JAMA 302:2437–2443PubMedCrossRef
26.
Zurück zum Zitat Gupta V, Gu K, Chen Z, Lu W, Shu XO, Zheng Y (2011) Concordance of self-reported and medical chart information on cancer diagnosis and treatment. BMC Med Res Methodol 11:72PubMedCrossRef Gupta V, Gu K, Chen Z, Lu W, Shu XO, Zheng Y (2011) Concordance of self-reported and medical chart information on cancer diagnosis and treatment. BMC Med Res Methodol 11:72PubMedCrossRef
27.
Zurück zum Zitat Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O’Brien WL, Bassett DR Jr, Schmitz KH, Emplaincourt PO et al (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32:S498–S504PubMedCrossRef Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O’Brien WL, Bassett DR Jr, Schmitz KH, Emplaincourt PO et al (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32:S498–S504PubMedCrossRef
28.
Zurück zum Zitat Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145:72–80PubMedCrossRef Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145:72–80PubMedCrossRef
29.
Zurück zum Zitat Kleinbaum D, Klien M (2005) Survival analysis: a self-learning text. Springer Science+Business Media, New York Kleinbaum D, Klien M (2005) Survival analysis: a self-learning text. Springer Science+Business Media, New York
30.
Zurück zum Zitat Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, Caan BJ (2012) Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomarkers Prev 21:1115–1125PubMedCrossRef Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, Caan BJ (2012) Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomarkers Prev 21:1115–1125PubMedCrossRef
31.
Zurück zum Zitat Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129:549–556PubMedCrossRef Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129:549–556PubMedCrossRef
32.
Zurück zum Zitat Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2008) The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 109:389–395PubMedCrossRef Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2008) The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 109:389–395PubMedCrossRef
33.
34.
Zurück zum Zitat Holmes MD, Chen WY (2012) Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res 14:216PubMedCrossRef Holmes MD, Chen WY (2012) Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res 14:216PubMedCrossRef
35.
Zurück zum Zitat Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1:628–638PubMed Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1:628–638PubMed
36.
Zurück zum Zitat Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29:2635–2644PubMedCrossRef Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29:2635–2644PubMedCrossRef
37.
Zurück zum Zitat Melhem-Bertrandt A, Chavez-MacGregor M, Lei XD, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645–2652PubMedCrossRef Melhem-Bertrandt A, Chavez-MacGregor M, Lei XD, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645–2652PubMedCrossRef
38.
Zurück zum Zitat Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ace inhibitors, ARBs, and/or statins. Cancer Invest 29:585–593PubMedCrossRef Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ace inhibitors, ARBs, and/or statins. Cancer Invest 29:585–593PubMedCrossRef
39.
Zurück zum Zitat Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW (1996) Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73–84PubMedCrossRef Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW (1996) Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73–84PubMedCrossRef
Metadaten
Titel
Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study
verfasst von
Sarah Nechuta
Wei Lu
Ying Zheng
Hui Cai
Ping-Ping Bao
Kai Gu
Wei Zheng
Xiao Ou Shu
Publikationsdatum
01.05.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2521-2

Weitere Artikel der Ausgabe 1/2013

Breast Cancer Research and Treatment 1/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.